AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 52 min read$VTRS

VTRS Maintained by UBS -- Price Target Raised to $26.00

UBS maintained a 'Buy' rating for Viatris (VTRS) and raised its price target to $26.00 from $23.00. GuruFocus values VTRS at $11.44, indicating a 54.0% overvaluation at its current price of $17.61. The company has a GF Score™ of 61/100, reflecting moderate financial health. 11 gurus hold VTRS, with mixed activity in recent quarters.

Original reporting
gurufocus.com
Published Oct 5, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 4:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VTRS
Bullish
medium confidence
Mentioned
$VTRS
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$VTRSBullishMed
01

Why it matters

Analyst rating upgrades can trigger short‑term buying, but valuation concerns persist.

02

Market read

The rating upgrade provides a modest trading signal for VTRS, with limited broader market impact.

03

What to watch

Negative earnings and cash‑flow concerns could limit upside despite the higher target.

Relevance 6/10Novelty 6/10Timing: today

Background

Viatris (VTRS) is a global generic drug maker formed from Pfizer's Upjohn and Mylan merger.

Company-level read

Ticker impact

$VTRSBullishMedium confidence
Context

UBS maintained a Buy rating and raised the price target for Viatris to $26, up from $23.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst target hikes are a common catalyst for short‑term buying, especially when the stock trades below the new target.

Market effects

Sector

May influence sentiment in the broader pharma/healthcare sector as peers are re‑priced.

Regional

Limited to U.S. markets where Viatris is listed.

Global

Low; the news is company‑specific.

Counterpoint

What could challenge this read

The stock remains overvalued per GF metrics; the target raise may be premature.

Key entities

  • Analyst
    UBS

    Raised VTRS price target to $26.

  • Company
    Viatris Inc.

    Subject of the rating update.

Read at source← All news

Related articles

OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.

medicaldialogues.in6 min
OCT 9
$VTRSHighAI 8/10

Viatris’ $36.50 Pacira Bid Looks Hard To Top

Viatris offered $36.50 per share to acquire Pacira, a 45% premium. Pacira's board supports the deal, and RBC raised its price target to the offer price. Pacira's stock traded near $36.31, indicating investor confidence in a swift closure.

finimize.com2 min
OCT 9
$VTRSHighAI 9/10

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Viatris (VTRS) agreed to acquire Pacira BioSciences (PCRX) for $1.65B in cash, or $36.50 per share. The deal expands VTRS's pain management portfolio, adding two marketed therapies and a gene therapy candidate. PCRX shares surged 44.4% post-announcement. The transaction is expected to close by the end of 2026 and is anticipated to be immediately accretive to VTRS's financial guidance. Pacira generated $746M in revenue and $177M in adjusted EBITDA in the 12 months ended June 30, 2026.

tradingview.com3 min
OCT 9
$VTRSHighAI 9/10

Viatris to Acquire Pacira in $1.65 Billion Deal

Viatris Inc. will acquire Pacira BioSciences Inc. for $1.65 billion, or $36.50 per share in cash. Pacira's products, EXPAREL and ZILRETTA, are expected to complement Viatris' portfolio and expand its reach in non-opioid pain management. Both companies' CEOs highlighted the strategic benefits of the deal, including accelerated growth and expanded patient access. According to Viatris, the acquisition advances its innovative medicines strategy and adds to its R&D capabilities.

contractpharma.com2 min